Please assess the completion status of the following clinical trial:

Trial Title: 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Japanese male or female patients with T2DM treated with diet and exercise alone or with one hypoglycaemic drug other than glitazones.~2. Hemoglobin A1c (HbA1c) at screening (Visit 1)~   * For patients treated with 1 other oral antidiabetic drug: HbA1c between 6.5% and 9.0%.~  * For patients not treated with any antidiabetic drug: HbA1c between 7.0% and 10.0%.~3. Age between 20 and 70 years~4. Body mass index (BMI) between18.0 and 40.0 kg/m2~5. Signed and dated written informed consent before admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation.~Exclusion criteria:~1. Antidiabetic treatment with insulin or glitazones within 3 months before obtaining informed consent or with more than 1 oral hypoglycaemic agent at the time of informed consent~2. Fasted blood glucose of \>240 mg/dL (\>13.3 mmol/L) or a randomly determined blood glucose level of \>400 mg/dL (22.2 mmol/L) on 2 consecutive days during wash-out period.~3. Myocardial infarction, stroke, or transient ischaemic attack within 6 months before informed consent.~4. Clinically relevant concomitant diseases other than T2DM, hyperlipidaemia, and medically treated hypertension before the first administration such as~   * Renal insufficiency (calculated estimated glomerular filtration rate \<60)~  * Cardiac insufficiency of New York Heart Association (NYHA) II-IV or other known cardiovascular diseases including hypertension of \>160/95 mmHg,~  * Neurological disorders (such as epilepsy) or psychiatric disorders~  * Acute or clinically relevant chronic infections (e.g., human immunodeficiency virus, hepatitis, repeated urogenital infections)~  * Any gastrointestinal, hepatic, respiratory, endocrine, or immunological disorder~5. Patients under treatment with any concomitant medication except for the following drugs at the time of informed consent.:~   * Statins.~  * Antihypertensives (diuretics not allowed)~  * alpha-Blockers for benign prostate hypertrophy~  * Occasional use of acetylsalicylic acid, ibuprofen, or paracetamol~6. Additional inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose quaque die (QD) (Type: EXPERIMENTAL): patient to receive a BI 10773 low dose tablet and a placebo tablet once daily
- BI 10773 mid-low dose QD (Type: EXPERIMENTAL): patient to receive a BI 10773 middle dose tablet and a placebo tablet once daily
- BI 10773 mid-high dose QD (Type: EXPERIMENTAL): patient to receive two tablets of BI 10773 middle dose once daily
- BI 10773 high dose QD (Type: EXPERIMENTAL): patient to receive a BI 10773 high dose tablet and a placebo tablet once daily
- Placebo (Type: PLACEBO_COMPARATOR): patient to receive two tablets of placebo once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete